Medicine Consents




NEW ZEALAND GAZETTE

16 MAY

1301

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Ursodeoxycholic acid 150 mg, 300 mg Capsules Ciba-Geigy AG., Stein, Switzerland and Giuliani SpA., Cernusco Sul Naviglio, Milan, Italy Actigall

Note: Provisional consent for this product expires on 7 September 1997.

Dated this 14th day of May 1996.

HUGH BABER, Assistant General Manager, Health Regulation and Protection, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.

go3160


Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name
Ipratropium bromide monohydrate 21 mcg equivalent to 20 mcg ipratropium bromide anhydrous per actuation Spray, oral metered dose Boehringer Ingelheim KG., Ingelheim am Rhein, Germany Atrovent Autohaler
Ganciclovir sodium 250 mg Capsule Syntex Puerto Rico Inc., Humacao, Puerto Rico Cymevene
Lactulose 100% in 10 g, 150 g, 200 g, 350 g, 700 g Powder for oral solution Solvay-Duphar BV., The Netherlands Duphalac Dry
Lignocaine 2.5%: prilocaine hydrochloride 2.5% Cream Astra Pharmaceutical Production AB, Södertälje, Sweden Emla Sterile Cream 5%
Estradiol 0.75 mg (delivery rate 25 mcg per day), 1.5 mg (delivery rate 50 mcg per day), 3 mg (delivery rate 100 mcg per day) Transdermal patch Lohmann Therapie Systeme GmbH & Co KG, Andernach, Germany Estraderm MX
Fluticasone propionate 50 mcg, 100 mcg, 250 mcg, 500 mcg Powder for oral inhalation Glaxo Operations UK Limited, Ware, Hertfordshire, United Kingdom Flixotide Accuhaler
Lenograstim 105 mcg Injection, powder for Chugai Pharmaceutical Co Limited, Utsunomiya, Tochigi, Japan Granocyte 13
Lenograstim 263 mcg Injection, powder for Chugai Pharmaceutical Co Limited, Utsunomiya, Tochigi, Japan Granocyte 34
Human immunoglobulin G 60 mg/mL in 50 mL, 200 mL, 500 mL Injection, solution CSL Limited, Broadmeadows, Victoria, Australia Intragam
Tibolone 2.5 mg Tablet Organon International BV., Oss, The Netherlands Livial
Gadopentetate dimeglumine 469 mg per mL in 5 mL, 10 mL, 15 mL and 20 mL Injection Schering AG., Berlin, Germany Magnevist
Tretinoin 0.05% w/w Cream Cilag AG., Schaffhausen, Switzerland; Johnson & Johnson Medical Products Pty Limited, North Ryde, Sydney, New South Wales, Australia; Ortho Pharmaceuticals Inc., Bo Campo Alegre Manati, Puerto Rico and Ortho Pharmaceuticals Corporation, Raritan, New Jersey, United States of America Retinova Emollient

Dated this 14th day of May 1996.

HUGH BABER, Assistant General Manager, Health Regulation and Protection, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.

go3161



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1996, No 48


NZLII PDF NZ Gazette 1996, No 48





✨ LLM interpretation of page content

🏥 Consent to the Distribution of a New Medicine (continued from previous page)

🏥 Health & Social Welfare
14 May 1996
Medicines Act, New Medicine, Ursodeoxycholic acid, Actigall
  • Hugh Baber, Assistant General Manager, Health Regulation and Protection

🏥 Consent to the Distribution of Changed Medicines

🏥 Health & Social Welfare
14 May 1996
Medicines Act, Changed Medicines, Ipratropium bromide, Ganciclovir sodium, Lactulose, Lignocaine, Estradiol, Fluticasone propionate, Lenograstim, Human immunoglobulin G, Tibolone, Gadopentetate dimeglumine, Tretinoin
  • Hugh Baber, Assistant General Manager, Health Regulation and Protection